Dapagliflozin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Dapagliflozin

Examples of brand names: Forxiga [EU/DE]

ATC code: A10BK01

Main use (for orientation): Diabetes; heart/renal failure

Documented research summary

Existing finding B0103 confirmed: a physiologically based pharmacokinetic model predicts increased dapagliflozin AUC with an assumed CBD regimen and UGT1A9 fraction. This is not a measured clinical interaction. No second database row created for the same finding.

Uncertainties and limitations

Model-article abstract read; model validation and sensitivity analyses not fully independently reconstructed.

Missing data do not establish safety. Research is limited by the documented sources, search terms, languages and accessibility.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – theoretical plausibility

Finding ID: B0103

Type of result: Context-specific finding; read the limitations

Observation: Predicted AUC increase of 126%.

Mechanism: UGT1A9 inhibition; PBPK

Study type: PBPK model based on in vitro data

Context studied: Model: repeated oral CBD 700 mg twice daily; dapagliflozin fm 0.80.

Clinical interpretation: Clinical relevance unresolved; validation needed

Limitations and uncertainties: Not an observed patient drug–drug interaction; not a dosing recommendation.

Original sources for this finding: Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations [ME04]

References and access status

[VD_LABEL_D0254] DAPAGLIFLOZIN TABLET, FILM COATED [ASCEND LABORATORIES, LLC] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[ME04] Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations

Original source / bibliographic reference

Authors: Bansal S; Paine MF; Unadkat JD

Year: 2025

Source type: Original study: in vitro UGT and PBPK

DOI: 10.1016/j.dmd.2025.100096

PMID: 40482431

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility